New response criteria proposed for immunotherapies.
Tuma
Rabiya S
RS
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D018450:Disease Progression; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D000074324:Ipilimumab; D009369:Neoplasms / Q000276:immunology / Q000401:mortality* / Q000628:therapy*; D016019:Survival Analysis; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome; D014944:World Health Organization
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000074324:Ipilimumab